Quantitative Measurement of Rate of Targeted Protein Degradation

被引:3
作者
Lynch, Thomas L. [1 ]
Marin, Violeta L. [2 ]
McClure, Ryan A. [2 ]
Phipps, Colin [1 ]
Ronau, Judith A. [2 ]
Rouhimoghadam, Milad [2 ]
Adams, Ashley M. [2 ]
Kandi, Soumya [1 ]
Wolke, Malerie L. [1 ]
Shergalis, Andrea G. [2 ]
Potts, Gregory K. [2 ]
Nacham, Omprakash [2 ]
Richardson, Paul [2 ]
Kakavas, Stephan J. [3 ]
Chhor, Gekleng [3 ]
Jenkins, Gary J. [1 ]
Woller, Kevin R. [2 ]
Warder, Scott E. [2 ]
Vasudevan, Anil [2 ]
Reitsma, Justin M. [2 ]
机构
[1] AbbVie Inc, Quantitat Translat & ADME Sci, N Chicago, IL 60064 USA
[2] AbbVie Inc, Technol & Therapeut Platforms, N Chicago, IL 60064 USA
[3] AbbVie Inc, Target Enabling Technol, N Chicago, IL 60064 USA
关键词
ANTIBODY-MEDIATED DELIVERY; BINDING; DRUGS; PROTACS; ENZYME;
D O I
10.1021/acschembio.4c00262
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Targeted protein degradation (TPD) is a therapeutic approach that leverages the cell's natural machinery to degrade targets instead of inhibiting them. This is accomplished by using mono- or bifunctional small molecules designed to induce the proximity of target proteins and E3 ubiquitin ligases, leading to ubiquitination and subsequent proteasome-dependent degradation of the target. One of the most significant attributes of the TPD approach is its proposed catalytic mechanism of action, which permits substoichiometric exposure to achieve the desired pharmacological effects. However, apart from one in vitro study, studies supporting the catalytic mechanism of degraders are largely inferred based on potency. A more comprehensive understanding of the degrader catalytic mechanism of action can help aspects of compound development. To address this knowledge gap, we developed a workflow for the quantitative measurement of the catalytic rate of degraders in cells. Comparing a selective and promiscuous BTK degrader, we demonstrate that both compounds function as efficient catalysts of BTK degradation, with the promiscuous degrader exhibiting faster rates due to its ability to induce more favorable ternary complexes. By leveraging computational modeling, we show that the catalytic rate is highly dynamic as the target is depleted from cells. Further investigation of the promiscuous kinase degrader revealed that the catalytic rate is a better predictor of optimal degrader activity toward a specific target compared to degradation magnitude alone. In summary, we present a versatile method for mapping the catalytic activity of any degrader for TPD in cells.
引用
收藏
页码:1604 / 1615
页数:12
相关论文
共 46 条
  • [1] Translational PK-PD for targeted protein degradation
    Bartlett, Derek W.
    Gilbert, Adam M.
    [J]. CHEMICAL SOCIETY REVIEWS, 2022, 51 (09) : 3477 - 3486
  • [2] PROTAC targeted protein degraders: the past is prologue
    Bekes, Miklos
    Langley, David R.
    Crews, Craig M.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (03) : 181 - 200
  • [3] BINDING OF BASIC AND ACIDIC DRUGS TO RAT TISSUE SUBCELLULAR-FRACTIONS
    BICKEL, MH
    STEELE, JW
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 1974, 8 (03) : 151 - 162
  • [4] Bondeson DP, 2015, NAT CHEM BIOL, V11, P611, DOI [10.1038/NCHEMBIO.1858, 10.1038/nchembio.1858]
  • [5] Targeting the C481S Ibrutinib-Resistance Mutation in Bruton's Tyrosine Kinase Using PROTAC-Mediated Degradation
    Buhimschi, Alexandru D.
    Armstrong, Haley A.
    Toure, Momar
    Jaime-Figueroa, Saul
    Chen, Timothy L.
    Lehman, Amy M.
    Woyach, Jennifer A.
    Johnson, Amy J.
    Byrd, John C.
    Crews, Craig M.
    [J]. BIOCHEMISTRY, 2018, 57 (26) : 3564 - 3575
  • [6] The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study
    Burslem, George M.
    Smith, Blake E.
    Lai, Ashton C.
    Jaime-Figueroa, Saul
    McQuaid, Daniel C.
    Bondeson, Daniel P.
    Toure, Momar
    Dong, Hanqing
    Qian, Yimin
    Wang, Jing
    Crew, Andrew P.
    Hines, John
    Crews, Craig M.
    [J]. CELL CHEMICAL BIOLOGY, 2018, 25 (01) : 67 - +
  • [7] Protein degraders enter the clinic - a new approach to cancer therapy
    Chirnomas, Deborah
    Hornberger, Keith R.
    Crews, Craig M.
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (04) : 265 - 278
  • [8] Multispecific drugs herald a new era of biopharmaceutical innovation
    Deshaies, Raymond J.
    [J]. NATURE, 2020, 580 (7803) : 329 - 338
  • [9] Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development
    Donovan, Katherine A.
    Ferguson, Fleur M.
    Bushman, Jonathan W.
    Eleuteri, Nicholas A.
    Bhunia, Debabrata
    Ryu, SeongShick
    Tan, Li
    Shi, Kun
    Yue, Hong
    Liu, Xiaoxi
    Dobrovolsky, Dennis
    Jiang, Baishan
    Wang, Jinhua
    Hao, Mingfeng
    You, Inchul
    Teng, Mingxing
    Liang, Yanke
    Hatcher, John
    Li, Zhengnian
    Manz, Theresa D.
    Groendyke, Brian
    Hu, Wanyi
    Nam, Yunju
    Sengupta, Sandip
    Cho, Hanna
    Shin, Injae
    Agius, Michael P.
    Ghobrial, Irene M.
    Ma, Michelle W.
    Che, Jianwei
    Buhrlage, Sara J.
    Sim, Taebo
    Gray, Nathanael S.
    Fischer, Eric S.
    [J]. CELL, 2020, 183 (06) : 1714 - +
  • [10] A Comprehensive Mathematical Model for Three-Body Binding Equilibria
    Douglass, Eugene F., Jr.
    Miller, Chad J.
    Sparer, Gerson
    Shapiro, Harold
    Spiegel, David A.
    [J]. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2013, 135 (16) : 6092 - 6099